Capricor Therapeutics, Inc.
CAPRCapricor Therapeutics, Inc. in brief
Capricor Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $356 M on 23 October 2026, which makes it the 14,039th largest listed company in the world and the 2,751st largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $105 M. It employs about 231 people and Linda Marban is its chief executive. Its largest business segments by sales in 2024 were Single reportable segment (100%). Its shares trade under the symbol CAPR (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy, a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have devoted substantial resources to the development of our lead product candidate, Deramiocel, a cell therapy designed to address the cardiac and skeletal muscle complications associated with DMD, as well as to advancing our exosome-based platform, developing manufacturing capabilities and supporting our research and development activities. Our Biologics License Application for Deramiocel for the treatment of DMD is currently under review by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act target action date of August 22, 2026, for potential approval in the United States. We currently have no products approved for commercial sale. Our ability to generate product revenue and achieve profitability will depend on the successful development, regulatory approval and commercialization of Deramiocel and any other product candidates we may develop. If approved, we intend to commercialize Deramiocel in the United States and may seek commercialization through strategic partners in other select international markets.
From the company's annual report filed with the US SEC: read the report
Capricor Therapeutics, Inc. timeline
- 2001
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2007
- ✎Renamed Nile Therapeutics, Inc.Formerly Smi Products Inc.
- 2013
- ✎Renamed Capricor Therapeutics, Inc.Formerly Nile Therapeutics, Inc..
- 2023
- 💰Record revenue of $25 millionFY2023, the highest of the 7 years on record.
Events of Capricor Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,755 (Jan 2020) · #3,853 (Jan 2021) · #4,653 (Jan 2022) · #4,377 (Dec 2022) · #4,096 (Jul 2023) · #3,384 (Jan 2024) · #689 (Mar 2026) · #2,694 (Aug 2026) · #2,659 (Oct 2026) · #2,755 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.2×
- Free cash flow yield
- -20.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -34.4%
- Liabilities / assets
- 14.1%
- Revenue growth
- -11.6%
- R&D / revenue
- 224.4%
- Revenue per employee
- $0 K
- Profit per employee
- $-455 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-108M | $-105M | — |
| Dec 2024 | $22M | -11.6% | $-43M | $-40M | -181.7% |
| Dec 2023 | $25M | +887.5% | $-24M | $-22M | -88.5% |
| Dec 2022 | $3M | +962.5% | $-30M | $-29M | -1138.0% |
| Dec 2021 | $0M | -22.6% | $-21M | $-20M | -8341.7% |
| Dec 2020 | $0M | -69.3% | $-14M | $-14M | -4406.5% |
| Dec 2019 | $1M | -39.5% | $-8M | $-8M | -756.4% |
| Dec 2018 | $2M | — | $-15M | $-15M | -909.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-70M | $3M | $-73M | $-2.26 | — |
| Dec 2024 | $-40M | $1M | $-41M | $-1.15 | — |
| Dec 2023 | $-26M | $1M | $-27M | $-0.83 | — |
| Dec 2022 | $5M | $2M | $3M | $-1.18 | — |
| Dec 2021 | $-17M | $1M | $-18M | $-0.87 | — |
| Dec 2020 | $-10M | $1M | $-11M | $-0.88 | — |
| Dec 2019 | $-7M | $0M | $-7M | $-2.06 | — |
| Dec 2018 | $-14M | $0M | $-14M | $-0.52 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-43M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 24, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jul 30, 20268-KCurrent reportOther events
- Jul 29, 20268-KCurrent reportOther events
- Jul 14, 20268-KCurrent reportMaterial agreement · New financial obligation
- Jun 26, 20268-KCurrent reportOther events
- Jun 8, 20268-KCurrent reportShareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
Official filings of Capricor Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-108 M
- Net income
- $-105 M
For year ending December-2025
Balance sheet
- Total assets
- $356 M
- Total liabilities
- $50 M
- Total equity
- $306 M
As of December-2025
Top 100 institutional investors in Capricor Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4,178,205 | +33,144 (+0.80%) | 7.19% | $40 M | Nov 13, 2026 |
| 2 | State Street Corp | 3,019,025 | -378,125 (-11.13%) | 5.19% | $29 M | Nov 12, 2026 |
| 3 | Ra Capital Management, L.P. | 3,014,183 | +1,506,339 (+99.90%) | 5.18% | $29 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 2,303,381 | +5,707 (+0.25%) | 3.96% | $22 M | Nov 13, 2026 |
| 5 | D. E. Shaw & Co., Inc. | 2,141,641 | +2,017,895 (+1630.67%) | 3.68% | $20 M | Nov 16, 2026 |
| 6 | Millennium Management LLC | 1,669,083 | +1,435,157 (+613.51%) | 2.87% | $16 M | Nov 16, 2026 |
| 7 | UBS Group AG | 1,403,356 | +783,695 (+126.47%) | 2.41% | $13 M | Nov 10, 2026 |
| 8 | EcoR1 Capital, LLC | 1,376,580 | New | 2.37% | $13 M | Nov 16, 2026 |
| 9 | Longaeva Partners L.P. | 1,231,841 | +1,157,795 (+1563.62%) | 2.12% | $12 M | Nov 16, 2026 |
| 10 | Geode Capital Management, LLC | 1,137,681 | -234,605 (-17.10%) | 1.96% | $11 M | Nov 6, 2026 |
| 11 | Two Sigma Investments, LP | 946,870 | New | 1.63% | $9 M | Nov 16, 2026 |
| 12 | Jones Hill Capital LP | 892,532 | +471,781 (+112.13%) | 1.54% | $8 M | Nov 13, 2026 |
| 13 | Perceptive Advisors LLC | 850,000 | New | 1.46% | $8 M | Nov 16, 2026 |
| 14 | Balyasny Asset Management L.P. | 812,718 | +325,882 (+66.94%) | 1.40% | $8 M | Nov 16, 2026 |
| 15 | Mercer Global Advisors Inc /adv | 808,610 | +5,878 (+0.73%) | 1.39% | $8 M | Nov 16, 2026 |
| 16 | Susquehanna International Group, LLP | 700,431 | +690,969 (+7302.57%) | 1.20% | $7 M | Nov 16, 2026 |
| 17 | Soleus Capital Management, L.P. | 699,149 | -62,588 (-8.22%) | 1.20% | $7 M | Nov 16, 2026 |
| 18 | Goldman Sachs Group Inc | 697,355 | -880,776 (-55.81%) | 1.20% | $7 M | Nov 16, 2026 |
| 19 | Point72 Asset Management, L.P. | 671,505 | +576,782 (+608.91%) | 1.15% | $6 M | Nov 16, 2026 |
| 20 | Boxer Capital Management, LLC | 642,837 | -752,319 (-53.92%) | 1.11% | $6 M | Nov 16, 2026 |
| 21 | Palo Alto Investors LP | 548,071 | +318,308 (+138.54%) | 0.94% | $5 M | Nov 16, 2026 |
| 22 | ADAR1 Capital Management, LLC | 526,996 | +436,403 (+481.72%) | 0.91% | $5 M | Nov 16, 2026 |
| 23 | Vanguard Portfolio Management LLC | 517,260 | -118,827 (-18.68%) | 0.89% | $5 M | Nov 13, 2026 |
| 24 | Northern Trust Corp | 508,100 | +4,568 (+0.91%) | 0.87% | $5 M | Nov 16, 2026 |
| 25 | Jump Financial, LLC | 480,286 | +457,250 (+1984.94%) | 0.83% | $5 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | National Bank Of Canada /fi/ | 399,300 | +399,289 (+3629900.00%) | 0.69% | $4 M | Nov 16, 2026 |
| 27 | Vanguard Fiduciary Trust Co | 379,254 | +6,715 (+1.80%) | 0.65% | $4 M | Nov 13, 2026 |
| 28 | Morgan Stanley | 377,740 | -306,775 (-44.82%) | 0.65% | $4 M | Nov 13, 2026 |
| 29 | Citigroup Inc | 360,665 | +280,542 (+350.14%) | 0.62% | $3 M | Nov 4, 2026 |
| 30 | Jpmorgan Chase & Co | 339,771 | -22,730 (-6.27%) | 0.58% | $3 M | Nov 12, 2026 |
| 31 | DG Capital Management, LLC | 279,558 | -332,037 (-54.29%) | 0.48% | $3 M | Nov 12, 2026 |
| 32 | Barclays PLC | 275,957 | +208,517 (+309.19%) | 0.47% | $3 M | Nov 6, 2026 |
| 33 | RTW Investments, LP | 250,000 | 0 (0.00%) | 0.43% | $2 M | Nov 16, 2026 |
| 34 | Quantinno Capital Management LP | 248,285 | +233,444 (+1572.97%) | 0.43% | $2 M | Nov 13, 2026 |
| 35 | Squarepoint Ops LLC | 238,892 | +219,161 (+1110.74%) | 0.41% | $2 M | Nov 9, 2026 |
| 36 | Ikarian Capital, LLC | 229,215 | -375,000 (-62.06%) | 0.39% | $2 M | Nov 16, 2026 |
| 37 | HBK Sorce Advisory LLC | 225,256 | +2,180 (+0.98%) | 0.39% | $2 M | Nov 6, 2026 |
| 38 | Cantor Fitzgerald, L. P. | 225,000 | New | 0.39% | $2 M | Nov 16, 2026 |
| 39 | Nuveen, LLC | 210,651 | -25,961 (-10.97%) | 0.36% | $2 M | Nov 10, 2026 |
| 40 | Corient Private Wealth LP | 205,343 | New | 0.35% | $2 M | Nov 16, 2026 |
| 41 | Oppenheimer & Co Inc | 203,781 | +128,067 (+169.15%) | 0.35% | $2 M | Oct 26, 2026 |
| 42 | Raymond James Financial Inc | 200,148 | +3,292 (+1.67%) | 0.34% | $2 M | Nov 12, 2026 |
| 43 | Caption Management, LLC | 175,750 | +103,750 (+144.10%) | 0.30% | $2 M | Nov 16, 2026 |
| 44 | Bank of New York Mellon Corp | 164,260 | +2,493 (+1.54%) | 0.28% | $2 M | Nov 5, 2026 |
| 45 | Charles Schwab Investment Management Inc | 161,010 | +72 (+0.04%) | 0.28% | $2 M | Nov 16, 2026 |
| 46 | State Of Wisconsin Investment Board | 160,896 | +94,008 (+140.55%) | 0.28% | $2 M | Nov 16, 2026 |
| 47 | Bank Of America Corp /de/ | 156,174 | -95,061 (-37.84%) | 0.27% | $1 M | Nov 16, 2026 |
| 48 | FMR LLC | 138,986 | -998,744 (-87.78%) | 0.24% | $1 M | Nov 10, 2026 |
| 49 | Group One Trading LLC | 133,714 | -138,895 (-50.95%) | 0.23% | $1 M | Nov 10, 2026 |
| 50 | Erste Asset Management GmbH | 112,000 | New | 0.19% | $1 M | Nov 12, 2026 |
| 51 | Swiss National Bank | 92,900 | 0 (0.00%) | 0.16% | $1 M | Nov 12, 2026 |
| 52 | Rock Springs Capital Management LP | 87,007 | +12,559 (+16.87%) | 0.15% | $1 M | Nov 16, 2026 |
| 53 | Trexquant Investment LP | 81,851 | -115,942 (-58.62%) | 0.14% | $1 M | Nov 16, 2026 |
| 54 | Deeter Investments LLP | 80,898 | New | 0.14% | $1 M | Nov 16, 2026 |
| 55 | Algert Global LLC | 79,200 | +48,590 (+158.74%) | 0.14% | $1 M | Nov 17, 2026 |
| 56 | Black Diamond Financial, LLC | 79,077 | 0 (0.00%) | 0.14% | $1 M | Oct 26, 2026 |
| 57 | LPL Financial LLC | 77,853 | +50,476 (+184.37%) | 0.13% | $1 M | Nov 6, 2026 |
| 58 | Rafferty Asset Management, LLC | 77,244 | +16,871 (+27.94%) | 0.13% | $1 M | Nov 13, 2026 |
| 59 | Boothbay Fund Management, LLC | 75,405 | -117,557 (-60.92%) | 0.13% | $1 M | Nov 16, 2026 |
| 60 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 75,200 | +770 (+1.03%) | 0.13% | $1 M | Nov 16, 2026 |
| 61 | Alliancebernstein L.P. | 69,500 | +12,200 (+21.29%) | 0.12% | $1 M | Nov 16, 2026 |
| 62 | Commonwealth Equity Services, LLC | 67,402 | +40,627 (+151.73%) | 0.12% | $1 M | Nov 2, 2026 |
| 63 | Rhumbline Advisers | 65,395 | -2,486 (-3.66%) | 0.11% | $1 M | Nov 10, 2026 |
| 64 | Citadel Advisors LLC | 62,600 | -751,844 (-92.31%) | 0.11% | $1 M | Nov 16, 2026 |
| 65 | Osaic Holdings, Inc. | 61,529 | +41,195 (+202.59%) | 0.11% | $1 M | Nov 12, 2026 |
| 66 | Quadrature Capital Ltd | 60,246 | New | 0.10% | $1 M | Nov 13, 2026 |
| 67 | Foundations Investment Advisors, LLC | 60,013 | +3 (0.00%) | 0.10% | $1 M | Nov 12, 2026 |
| 68 | Axq Capital, LP | 58,575 | New | 0.10% | $1 M | Nov 12, 2026 |
| 69 | California State Teachers Retirement System | 54,625 | -8,850 (-13.94%) | 0.09% | $1 M | Nov 13, 2026 |
| 70 | Deutsche Bank AG\ | 54,214 | -3,365 (-5.84%) | 0.09% | $1 M | Nov 6, 2026 |
| 71 | Exome Asset Management LLC | 51,531 | New | 0.09% | $0 M | Nov 16, 2026 |
| 72 | Creative Planning | 48,486 | +29,899 (+160.86%) | 0.08% | $0 M | Nov 2, 2026 |
| 73 | Gsa Capital Partners LLP | 46,182 | New | 0.08% | $0 M | Nov 16, 2026 |
| 74 | Price T Rowe Associates Inc /MD/ | 44,748 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 75 | Simplex Trading, LLC | 42,344 | New | 0.07% | $0 M | Nov 4, 2026 |
| 76 | Lighthouse Investment Partners, LLC | 40,000 | New | 0.07% | $0 M | Nov 16, 2026 |
| 77 | Legal & General Group Plc | 38,513 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 78 | Entropy Technologies, LP | 36,202 | New | 0.06% | $0 M | Nov 13, 2026 |
| 79 | Dauntless Investment Group, LLC | 35,000 | +34,999 (+3499900.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 80 | VANGUARD ASSET MANAGEMENT, Ltd | 32,265 | 0 (0.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 31,658 | -121 (-0.38%) | 0.05% | $0 M | Nov 16, 2026 |
| 82 | Shay Capital LLC | 30,000 | New | 0.05% | $0 M | Nov 16, 2026 |
| 83 | Profund Advisors LLC | 27,231 | -3,251 (-10.67%) | 0.05% | $0 M | Oct 29, 2026 |
| 84 | Invesco Ltd. | 27,121 | -2,431 (-8.23%) | 0.05% | $0 M | Nov 12, 2026 |
| 85 | SBI Securities Co., Ltd. | 26,310 | +23,495 (+834.64%) | 0.05% | $0 M | Oct 22, 2026 |
| 86 | Capital Fund Management S.A. | 25,911 | New | 0.04% | $0 M | Nov 13, 2026 |
| 87 | MetLife Investment Management, LLC | 25,767 | -5,613 (-17.89%) | 0.04% | $0 M | Nov 16, 2026 |
| 88 | Connective Capital Management, LLC | 25,552 | New | 0.04% | $0 M | Nov 16, 2026 |
| 89 | Caitong International Asset Management Co., Ltd | 22,754 | New | 0.04% | $0 M | Oct 29, 2026 |
| 90 | Janus Henderson Group Ltd. | 22,600 | — | 0.04% | $0 M | Nov 16, 2026 |
| 91 | Cerity Partners LLC | 21,304 | New | 0.04% | $0 M | Nov 13, 2026 |
| 92 | Tower Research Capital LLC (TRC) | 20,195 | +17,342 (+607.85%) | 0.03% | $0 M | Nov 16, 2026 |
| 93 | VestGen Advisors, LLC | 20,164 | New | 0.03% | $0 M | Oct 27, 2026 |
| 94 | Sculptor Capital LP | 20,000 | New | 0.03% | $0 M | Nov 13, 2026 |
| 95 | Vanguard Global Advisers, LLC | 19,952 | -8,600 (-30.12%) | 0.03% | $0 M | Nov 13, 2026 |
| 96 | Federated Hermes, Inc. | 19,580 | New | 0.03% | $0 M | Nov 12, 2026 |
| 97 | New York State Common Retirement Fund | 18,600 | -300 (-1.59%) | 0.03% | $0 M | Nov 17, 2026 |
| 98 | BNP Paribas Financial Markets | 17,403 | +6,824 (+64.51%) | 0.03% | $0 M | Nov 12, 2026 |
| 99 | Russell Investments Group, Ltd. | 17,326 | +3,036 (+21.25%) | 0.03% | $0 M | Nov 6, 2026 |
| 100 | Wells Fargo & Company/mn | 16,444 | -36,744 (-69.08%) | 0.03% | $0 M | Nov 16, 2026 |
Mutual funds holding Capricor Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 2.18 M | $52 M | 2.2% | 0.49% | +86% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.66 M | $40 M | 1.7% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.40 M | $34 M | 1.4% | 0.04% | +32% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 591,508 | $14 M | 0.59% | 0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 496,401 | $12 M | 0.50% | 0.08% | +39% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 334,200 | $10 M | 0.33% | 0.19% | +6.2% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 238,101 | $7 M | 0.24% | 0.02% | −1.1% | May 31, 2026 |
| 🇺🇸 Select Pharmaceuticals PortfolioFidelity Management & Research Company LLC | 231,300 | $7 M | 0.23% | 0.46% | −41% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 223,876 | $7 M | 0.22% | 0.04% | +17% | May 31, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 190,170 | $6 M | 0.19% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC | 87,370 | $3 M | 0.09% | 0.63% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 86,770 | $3 M | 0.09% | <0.01% | +2.0% | May 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 85,131 | $3 M | 0.09% | 0.14% | +156% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 100,532 | $2 M | 0.10% | 0.04% | +42% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 587,905 | $2 M | 0.59% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 69,945 | $2 M | 0.07% | <0.01% | +2.7% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 66,615 | $2 M | 0.07% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 58,475 | $1 M | 0.06% | 0.04% | +29% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 54,655 | $1 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 40,983 | $1 M | 0.04% | 0.07% | +16% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 50,388 | $1 M | 0.05% | 0.08% | +52% | Jun 30, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 48,562 | $1 M | 0.05% | 0.10% | −6.7% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 35,895 | $1 M | 0.04% | 0.02% | −1.2% | May 29, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 34,872 | $1 M | 0.03% | <0.01% | +8.2% | May 31, 2026 |
| 🇸🇪 SEB Nordamerikafond SmåbolagSEB Funds AB | 41,567 | $1 M | 0.04% | 0.36% | +163% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 38,100 | $1 M | 0.04% | 0.04% | +45% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 31,880 | $1 M | 0.03% | 0.04% | +52% | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 20,771 | $1 M | 0.02% | 0.38% | — | Apr 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 27,170 | $1 M | 0.03% | 0.04% | +36% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 25,820 | $1 M | 0.03% | <0.01% | −4.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 25,137 | $1 M | 0.03% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 19,594 | $1 M | 0.02% | 0.07% | new | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 17,130 | $1 M | 0.02% | 0.04% | +8.0% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 130,634 | $1 M | 0.13% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 20,496 | $0 M | 0.02% | 0.06% | +17% | Jun 30, 2026 |
| 🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation | 19,492 | $0 M | 0.02% | 0.05% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 19,310 | $0 M | 0.02% | 0.02% | +45% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 15,068 | $0 M | 0.02% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 18,000 | $0 M | 0.02% | 0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 17,789 | $0 M | 0.02% | 0.04% | +34% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 110,633 | $0 M | 0.11% | <0.01% | +207% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 16,462 | $0 M | 0.02% | 0.04% | +21% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 16,452 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 15,444 | $0 M | 0.02% | 0.04% | +36% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 14,045 | $0 M | 0.01% | 0.08% | −2.8% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 12,886 | $0 M | 0.01% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 10,262 | $0 M | 0.01% | 0.03% | −48% | May 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 11,904 | $0 M | 0.01% | 0.04% | +39% | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 73,804 | $0 M | 0.07% | 0.06% | +10.0% | Jul 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 10,837 | $0 M | 0.01% | 0.11% | −5.3% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 10,763 | $0 M | 0.01% | 0.04% | +36% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 66,406 | $0 M | 0.07% | <0.01% | +27% | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 7,200 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 8,554 | $0 M | <0.01% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 6,766 | $0 M | <0.01% | 0.12% | — | Mar 31, 2026 |
| 🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY | 6,778 | $0 M | <0.01% | 0.06% | new | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 8,300 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 8,294 | $0 M | <0.01% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 8,287 | $0 M | <0.01% | 0.04% | +36% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 8,203 | $0 M | <0.01% | 0.04% | +60% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,894 | $0 M | <0.01% | 0.04% | +34% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 7,253 | $0 M | <0.01% | 0.04% | +36% | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 7,133 | $0 M | <0.01% | 0.05% | −5.0% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 6,766 | $0 M | <0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,519 | $0 M | <0.01% | 0.04% | +38% | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 40,091 | $0 M | 0.04% | <0.01% | −36% | Jul 31, 2026 |
| 🇺🇸 Putnam Dynamic Asset Allocation Growth FundFranklin Advisers, Inc. | 6,278 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,881 | $0 M | <0.01% | 0.04% | +37% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 30,264 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 4,759 | $0 M | <0.01% | 0.08% | +47% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 28,172 | $0 M | 0.03% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 3,531 | $0 M | <0.01% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 Putnam Dynamic Asset Allocation Balanced FundFranklin Advisers, Inc. | 4,358 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 4,295 | $0 M | <0.01% | 0.04% | +47% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 4,242 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 25,706 | $0 M | 0.03% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors | 2,986 | $0 M | <0.01% | 0.01% | new | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 3,638 | $0 M | <0.01% | 0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,601 | $0 M | <0.01% | 0.04% | +33% | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 21,985 | $0 M | 0.02% | <0.01% | −2.1% | Jul 31, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 3,401 | $0 M | <0.01% | 0.06% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 18,822 | $0 M | 0.02% | <0.01% | +17% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 2,051 | $0 M | <0.01% | 0.03% | +23% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,322 | $0 M | <0.01% | <0.01% | −23% | Jun 30, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 2,290 | $0 M | <0.01% | 0.04% | −9.1% | Jun 30, 2026 |
| 🇺🇸 JPMorgan BetaBuilders U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc. | 14,178 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,622 | $0 M | <0.01% | 0.01% | −32% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,604 | $0 M | <0.01% | 0.02% | −33% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,885 | $0 M | <0.01% | 0.02% | +33% | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 1,350 | $0 M | <0.01% | <0.01% | −4.9% | May 31, 2026 |
| 🇺🇸 Multimanager Aggressive Equity PortfolioEquitable Investment Management Group, LLC | 1,600 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,500 | $0 M | <0.01% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,358 | $0 M | <0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,034 | $0 M | <0.01% | <0.01% | +30% | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 7,732 | $0 M | <0.01% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,142 | $0 M | <0.01% | <0.01% | +3.9% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 6,046 | $0 M | <0.01% | <0.01% | +8.1% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 5,983 | $0 M | <0.01% | <0.01% | +42% | Jul 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 886 | $0 M | <0.01% | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 886 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Capricor Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Karen KrasneyEVP, GENERAL COUNSEL | Option exercise | +24,100 | $3.180 | $77 K | 54,647 | Form 4 |
| filed | Anthony BergmannCHIEF FINANCIAL OFFICER | Option exercise | +24,100 | $3.180 | $77 K | 35,323 | Form 4 |
| filed | Anthony BergmannCHIEF FINANCIAL OFFICER | Sell10b5-1 plan | -24,100 | $30.38 | — | 11,223 | Form 4 |
| filed | Karen KrasneyEVP, GENERAL COUNSEL | Sell10b5-1 plan | -24,100 | $30.38 | $732 K | 30,547 | Form 4 |
| filed | Karen KrasneyEVP, GENERAL COUNSEL | Option exercise | +400 | $3.180 | $1 K | 30,947 | Form 4 |
| filed | Anthony BergmannCHIEF FINANCIAL OFFICER | Option exercise | +400 | $3.180 | $1 K | 11,623 | Form 4 |
| filed | Karen KrasneyEVP, GENERAL COUNSEL | Sell10b5-1 plan | -400 | $30.00 | $12 K | 30,547 | Form 4 |
| filed | Anthony BergmannCHIEF FINANCIAL OFFICER | Sell10b5-1 plan | -400 | $30.00 | — | 11,223 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Capricor Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2019 | Q4 2019 | $0M |
| Q3 2019 | Q3 2019 | $0M |
| Q4 2018 | Q4 2019 | $0M |
| Q3 2018 | Q3 2019 | $0M |
Trading halts
- 2026-07-29 10:55 UTC, code T3, resumed 11:05 UTC
- 2025-12-03 15:17 UTC, code LUDP, resumed 15:22 UTC
- 2025-12-03 15:07 UTC, code LUDP, resumed 15:17 UTC
- 2025-12-03 14:44 UTC, code LUDP, resumed 15:04 UTC
- 2025-12-03 14:36 UTC, code LUDP, resumed 14:41 UTC
Fails to deliver
- : 8,926 shares at $6.13
- : 2,949 shares at $6.71
- : 233 shares at $6.88
- : 2,869 shares at $7.47
- : 34,495 shares at $8.10
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Capricor Therapeutics, Inc. scorecard#
Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 23, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-20.4%Free cash flow is -20.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.26 vs -1.15Diluted EPS -2.26 in fiscal 2025 against -1.15 the year before (report's currency).
- ✗Net income higher than five years earlier-$105 M-$105 M in fiscal 2025 against -$14 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$105 MNet income -$105 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-46.6%-46.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities9.0×Current ratio 9.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year32.0%Diluted shares up 32.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Capricor Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0−100%— | 22−11.5%100% | 25+887%100% | 2.6+942%100% | 0.2−21.1%100% | 0.3−69.1%100% | 1.0−39.9%100% | 1.7−37.3%100% | 2.7−33.3%100% | 4.0—100% | |
| Research and development | 84+69.0%— | 50+37.1%224% | 36+67.1%145% | 22+60.8%855% | 14+60.5%5542% | 8.5+64.5%2726% | 5.1−57.4%512% | 12+12.1%722% | 11−32.9%404% | 16—401% | |
| General and administrative | 24+59.3%— | 15r15+16.1%66.7% | 13+22.8%50.9% | 10+37.0%409% | 7.6+37.3%3108% | 5.5+54.1%1787% | 3.6−27.1%358% | 4.9+3.5%295% | 4.8−3.5%179% | 4.9—123% | |
| Operating expenses | 108+66.8%— | 65r65+31.6%291% | 49+52.7%196% | 32+52.2%1264% | 21+51.3%8650% | 14+60.2%4513% | 8.7−48.6%870% | 17+9.5%1017% | 16−26.0%582% | 21—525% | |
| Operating income | −108—— | −43r−43—−191% | −24—−95.6% | −30—−1164% | −21—−8550% | −14—−4413% | −7.7—−770% | −15—−917% | −13—−482% | −17—−425% | |
| Interest and finance income | 6.3+184%— | 2.2+27.4%9.9% | 1.7+231%6.9% | 0.5+808%20.4% | 0.1+74.4%23.5% | 0.0−65.2%10.6% | 0.1−30.3%9.4% | 0.1+253%8.1% | 0.0+167%1.4% | 0.0—0.4% | |
| Interest expense and finance costs | 3.0—— | 0—0.0% | — | — | — | — | — | 0−100%0.0% | 0.4+15.7%15.0% | 0.3—8.6% | |
| Other non-operating income (expense) | 3.1+47.8%— | 2.1+17.2%9.4% | 1.8+164%7.1% | 0.7−26.0%26.6% | 0.9+2680%374% | 0.0−64.2%10.6% | 0.1−32.3%9.2% | 0.1−99.1%8.1% | 15—574% | −1.8—−45.8% | |
| Income before tax | −105—— | −40—−182% | — | — | — | — | — | — | — | — | |
| Income tax | 0.00.0%— | 0.0—0.0% | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −105—— | −40—−182% | −22—−88.5% | −29—−1137% | −20—−8176% | −14—−4402% | — | — | — | — | |
| Net income attributable to shareholders | −105—— | −40—−182% | −22—−88.5% | −29—−1137% | −20—−8176% | −14—−4402% | −7.6—−760% | −15−725%−909% | 2.4—91.2% | −19—−470% | |
| Earnings per share, basic | -2.26—— | -1.15—— | -0.83—— | -1.18—— | -0.87—— | -0.88—— | -2.06—— | -5.17r-0.52−5270%— | 0.10—— | -1.01—— | |
| Earnings per share, diluted | -2.26—— | -1.15—— | -0.83—— | -1.18—— | -0.87—— | -0.88—— | -2.06—— | -0.52−678%— | 0.09—— | -1.01—— | |
| Shares, weighted average (basic) | 46+32.0%— | 35+31.5%— | 27+9.1%— | 25+6.3%— | 23+48.3%— | 16+320%— | 3.7+26.2%— | 2.9r29−87.3%— | 23+25.0%— | 19—— | |
| Shares, weighted average (diluted) | 46+32.0%— | 35+31.5%— | 27+9.1%— | 25+6.3%— | 23+48.3%— | 16+320%— | 3.7+26.2%— | 2.9r29−89.0%— | 27+44.4%— | 19—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 288+2450%80.9% | 11−23.2%6.6% | 15+53.0%25.0% | 9.6−72.5%19.2% | 35+6.8%84.4% | 33+738%94.4% | 3.9−8.5%35.1% | 4.3−30.6%46.1% | 6.1+91.6%37.7% | 3.2—17.1% | |
| Short-term investments | 30−78.4%8.5% | 140+466%82.3% | 25−22.1%42.2% | 32—63.5% | 0—0.0% | — | 6.0+99.7%53.9% | 3.0−62.5%32.4% | 8.0−38.5%49.1% | 13—69.3% | |
| Other current assets | 4.8r4.8+221%1.4% | 1.5+50.7%0.9% | 1.0+8.2%1.7% | 0.9−20.7%1.8% | 1.2+14.7%2.8% | 1.0+77.0%2.9% | 0.6−21.1%5.1% | 0.7+44.5%7.8% | 0.5+46.2%3.1% | 0.3—1.8% | |
| Current assets | 323+97.7%90.7% | 163+221%95.8% | 51+18.6%86.6% | 43+17.7%85.6% | 36+8.2%88.2% | 34+219%97.3% | 11+24.5%94.9% | 8.5−46.1%91.6% | 16−13.2%96.6% | 18—96.6% | |
| Property, plant and equipment | 18+229%5.1% | 5.6+0.0%3.3% | 5.6+21.2%9.5% | 4.6+156%9.2% | 1.8+111%4.3% | 0.9+92.1%2.5% | 0.4−22.9%4.0% | 0.6+54.3%6.2% | 0.4−14.5%2.3% | 0.4—2.3% | |
| Right-of-use (leased) assets | 14+931%3.8% | 1.3−36.0%0.8% | 2.1−12.8%3.5% | 2.3−16.7%4.7% | 2.8—6.8% | 0—0.0% | — | — | — | — | |
| Other intangible assets | — | — | — | — | 0−100%0.0% | 0.0−66.7%0.0% | 0.0−87.0%0.1% | 0.0−46.5%0.5% | 0.1−34.6%0.6% | 0.1—0.8% | |
| Total assets | 356+109%100% | 170+190%100% | 59+17.2%100% | 50+21.2%100% | 41+19.4%100% | 35+211%100% | 11+20.2%100% | 9.2−43.2%100% | 16−13.2%100% | 19—100% | |
| Accounts payable | 1.7−49.6%0.5% | 3.3r8.2−47.5%1.9% | 6.3r6.2+29.3%10.6% | 4.8+55.1%9.7% | 3.1+14.8%7.5% | 2.7r2.7+202%7.8% | 0.9r0.9−21.8%8.1% | 1.1−23.2%12.4% | 1.5−50.8%9.2% | 3.0—16.2% | |
| Current liabilities | 36+70.4%10.1% | 21−32.8%12.3% | 31+32.6%53.2% | 24+471%47.1% | 4.1+39.1%10.0% | 3.0+231%8.6% | 0.9−28.5%8.1% | 1.3−24.9%13.6% | 1.7−65.9%10.3% | 4.9—26.1% | |
| Lease liabilities (non-current) | 14+2224%4.0% | 0.6−58.5%0.4% | 1.5−20.8%2.5% | 1.9−23.4%3.7% | 2.5—5.9% | 0—0.0% | — | — | — | — | |
| Non-current liabilities | 14+259%4.0% | 4.0−17.9%2.3% | 4.9−67.0%8.3% | 15+153%29.4% | 5.8+69.1%14.1% | 3.4+2.1%10.0% | 3.40.0%30.4% | 3.40.0%36.5% | 3.4−81.1%20.7% | 18—95.2% | |
| Total liabilities | 50+100%14.1% | 25−30.8%14.7% | 36−5.7%61.5% | 38+285%76.5% | 10.0+55.2%24.1% | 6.4+50.2%18.5% | 4.3−7.7%38.5% | 4.6−8.2%50.1% | 5.0−77.8%31.0% | 23—121% | |
| Retained earnings | −305—−85.7% | −200—−117% | −159—−271% | −137—−274% | −108—−261% | −88—−254% | −74—−669% | −67—−722% | −52—−317% | −54—−288% | |
| Shareholders' equity | 306+110%85.9% | 145+544%85.3% | 23+91.8%38.5% | 12−62.4%23.5% | 31+11.2%75.9% | 28+312%81.5% | 6.8+48.2%61.5% | 4.6−58.9%49.9% | 11—69.0% | −4.0—−21.4% | |
| Total liabilities and equity | 356+109%100% | 170+190%100% | 59+17.2%100% | 50+21.2%100% | 41+19.4%100% | 35+211%100% | 11+20.2%100% | 9.2−43.2%100% | 16−13.2%100% | 19—100% | |
| Shares outstanding | 57+25.9%— | 46+46.3%— | 31+23.4%— | 25+4.4%— | 24+17.5%— | 21+294%— | 5.2+66.5%— | 3.1r31−88.1%— | 26+22.8%— | 21—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.9+32.5%— | 1.4+33.3%6.4% | 1.1+100%4.2% | 0.5+117%20.9% | 0.2+70.8%100% | 0.1−16.3%46.4% | 0.2+9.1%17.1% | 0.2+9.3%9.4% | 0.1+14.7%5.4% | 0.1—3.1% | |
| Share-based compensation | 17+76.4%— | 9.8+32.1%43.8% | 7.4+65.8%29.4% | 4.5+50.3%175% | 3.0+51.9%1211% | 2.0+179%629% | 0.7−59.4%69.7% | 1.7+0.9%103% | 1.7−12.8%64.2% | 2.0—49.1% | |
| Cash from operating activities | −70—— | −40—−180% | −26−621%−102% | 4.9—193% | −17—−6864% | −10—−3241% | −6.8—−679% | −14—−829% | −14—−534% | −14r−16—−361% | |
| Capital expenditure | −2.9—— | −1.2—−5.2% | −1.3—−5.2% | −2.0—−78.4% | −1.2—−488% | −0.5—−177% | 0—0.0% | −0.3—−18.9% | −0.0—−1.2% | −0.2—−4.8% | |
| Cash from investing activities | 97—— | −116−2374%−522% | 5.1—20.3% | −35—−1375% | −1.2−122%−488% | 5.4—1753% | −3.0−164%−299% | 4.7−6.2%280% | 5.0—187% | −5.2—−130% | |
| Debt issued | — | — | — | — | — | — | — | 0−100%0.0% | 0.5−89.5%18.8% | 4.8—119% | |
| Shares issued | 237+55.6%— | 152+497%684% | 26+431%101% | 4.8−76.2%188% | 20−26.2%8238% | 27+198%8813% | 9.2+36.6%913% | 6.7−39.4%402% | 11−20.1%415% | 14—347% | |
| Shares bought back | — | — | — | — | — | 0—0.0% | −0.0—−0.0% | 0—0.0% | — | — | |
| Cash from financing activities | 249+62.9%— | 153+497%686% | 26+425%102% | 4.9−75.9%191% | 20−39.4%8259% | 33+264%10760% | 9.2+33.9%913% | 6.9−40.8%410% | 12−37.8%434% | 19—466% | |
| Change in cash | — | — | — | — | — | — | — | — | — | −2.4—−59.1% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | 11*−7.9%100% | 2.3—100% | 4.0—100% | 4.9—100% | 12*—100% | |
| Research and development | 109+43.6%— | 30+45.2%— | 29+30.9%— | 27+44.7%— | 23*+58.9%— | 20+72.4%— | 22+76.3%— | 19+70.4%— | 15*+46.4%131% | 12—522% | 13—315% | 11—226% | 9.9*—82.2% | |
| General and administrative | 45+103%— | 15+155%— | 14+148%— | 9.4+54.9%— | 6.0r6.0*+41.0%— | 5.9+71.1%— | 5.7r5.7+85.4%— | 6.1+49.0%— | 4.3r4.3*+24.6%38.4% | 3.5—153% | 3.1—77.0% | 4.1—83.0% | 3.4*—28.4% | |
| Operating expenses | 154+57.0%— | 45+70.0%— | 43+54.9%— | 37+47.2%— | 29r29*+54.9%— | 26+72.1%— | 28r28+78.1%— | 25+64.7%— | 19r19*+40.8%169% | 15—675% | 16—392% | 15—309% | 13*—111% | |
| Operating income | −154—— | −45—— | −43—— | −37—— | −29r−29*—— | −26—— | −28r−28—— | −25—— | −7.7r−7.7*—−69.1% | −13—−575% | −12—−292% | −10—−209% | −1.3*—−10.6% | |
| Interest and finance income | 9.2+86.1%— | 2.0+18.2%— | 2.2+23.3%— | 2.9+298%— | 2.0*+194%— | 1.7+278%— | 1.8+203%— | 0.7+54.6%— | 0.7*+51.8%6.2% | 0.5—20.0% | 0.6—14.9% | 0.5—9.6% | 0.5*—3.7% | |
| Other non-operating income (expense) | 6.1+29.1%— | 2.0+18.3%— | 2.2+22.4%— | 2.8+379%— | −1.0*−274%— | 1.7+278%— | 1.8+206%— | 0.6+25.3%— | 0.6*+11.9%5.2% | 0.5—20.0% | 0.6—14.9% | 0.5—9.6% | 0.5*—4.3% | |
| Income before tax | −148—— | −43—— | −41—— | −34—— | −30*—— | −25—— | −26—— | −24—— | — | — | — | — | — | |
| Income tax | 0.0—— | 0*—— | 0.00.0%— | 0—— | 0*—— | 0*—— | 0.0—— | 0—— | — | — | — | — | — | |
| Net income including minority interests | −148—— | −43*—— | −41*—— | −34—— | −30*—— | −25*—— | −26*—— | −24—— | −7.1*—−63.9% | −13*—−555% | −11*—−277% | −9.8—−200% | −0.8*—−6.3% | |
| Net income attributable to shareholders | −148—— | −43—— | −41—— | −34—— | −30*—— | −25—— | −26—— | −24—— | −7.1*—−63.9% | −13—−555% | −11—−277% | −9.8—−200% | −0.8*—−6.3% | |
| Earnings per share, basic | — | -0.73—— | -0.70—— | -0.59—— | — | -0.54—— | -0.57—— | -0.53—— | — | -0.38—— | -0.35—— | -0.31—— | — | |
| Earnings per share, diluted | — | -0.73—— | -0.70—— | -0.59—— | — | -0.54—— | -0.57—— | -0.53—— | — | -0.38—— | -0.35—— | -0.31—— | — | |
| Shares, weighted average (basic) | 58+27.2%— | 58+27.2%— | 58+26.7%— | 57+25.9%— | — | 46+38.2%— | 46+43.5%— | 46+45.5%— | — | 33—— | 32—— | 31—— | — | |
| Shares, weighted average (diluted) | 58+27.2%— | 58+27.2%— | 58+26.7%— | 57+25.9%— | — | 46+38.2%— | 46+43.5%— | 46+45.5%— | — | 33—— | 32—— | 31—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 44—13.4% | 44+127%13.4% | 21−9.9%5.7% | 105+266%32.3% | 288+2450%80.9% | 20−71.5%15.4% | 23+117%17.4% | 29+363%18.7% | 11−23.2%6.6% | 68—73.6% | 11—27.9% | 6.2—12.6% | 15—25.0% | |
| Short-term investments | 153—46.4% | 153+93.9%46.4% | 217+118%58.8% | 173+49.3%53.1% | 30−78.4%8.5% | 79+375%62.5% | 100+430%74.5% | 116+244%75.4% | 140+466%82.3% | 17—17.9% | 19—49.0% | 34—68.2% | 25—42.2% | |
| Other current assets | 4.7—1.4% | 4.7+101%1.4% | 4.2+231%1.1% | 4.5+217%1.4% | 4.8r4.8+221%1.4% | 2.3+504%1.8% | 1.3+51.3%0.9% | 1.4+25.6%0.9% | 1.5+50.7%0.9% | 0.4—0.4% | 0.8—2.2% | 1.1—2.3% | 1.0—1.7% | |
| Current assets | 202—61.2% | 202+100%61.2% | 242+95.1%65.7% | 283+93.6%86.8% | 323+97.7%90.7% | 101+17.6%79.8% | 124+305%92.9% | 146+253%95.1% | 163+221%95.8% | 86—92.3% | 31—80.1% | 41—83.8% | 51—86.6% | |
| Property, plant and equipment | 38—11.4% | 38+240%11.4% | 36+355%9.9% | 29+365%8.7% | 18+229%5.1% | 11+108%8.8% | 8.0+42.3%6.0% | 6.1+4.1%4.0% | 5.6+0.0%3.3% | 5.3—5.7% | 5.6—14.7% | 5.9—11.9% | 5.6—9.5% | |
| Right-of-use (leased) assets | 87—26.4% | 87+525%26.4% | 89+9335%24.0% | 13+1067%4.0% | 14+931%3.8% | 14+833%11.0% | 0.9−43.8%0.7% | 1.1−38.9%0.7% | 1.3−36.0%0.8% | 1.5—1.6% | 1.7—4.4% | 1.8—3.7% | 2.1—3.5% | |
| Total assets | 330—100% | 330+161%100% | 369+176%100% | 326+112%100% | 356+109%100% | 126+36.0%100% | 134+249%100% | 154+211%100% | 170+190%100% | 93—100% | 38—100% | 49—100% | 59—100% | |
| Accounts payable | 3.0—0.9% | 3.0+12.1%0.9% | 3.1−36.0%0.8% | 3.9−25.2%1.2% | 1.7−49.6%0.5% | 2.7−58.4%2.2% | 4.8−22.0%3.6% | 5.3−15.9%3.4% | 3.3r8.2−47.5%1.9% | 6.5—7.0% | 6.2—16.1% | 6.2—12.6% | 6.3r6.2—10.6% | |
| Current liabilities | 30—9.0% | 30+6.2%9.0% | 33+16.1%8.9% | 34+50.6%10.3% | 36+70.4%10.1% | 28+37.5%22.3% | 28+27.0%21.3% | 22−15.3%14.5% | 21−32.8%12.3% | 20—22.0% | 22—58.4% | 26—53.4% | 31—53.2% | |
| Lease liabilities (non-current) | 91—27.5% | 91+529%27.5% | 90+45920%24.3% | 14+3323%4.3% | 14+2224%4.0% | 14+1627%11.4% | 0.2−81.4%0.1% | 0.4−67.4%0.3% | 0.6−58.5%0.4% | 0.8—0.9% | 1.0—2.7% | 1.2—2.5% | 1.5—2.5% | |
| Non-current liabilities | 91—27.5% | 91+529%27.5% | 90+45920%24.3% | 14+269%4.3% | 14+259%4.0% | 14+242%11.4% | 0.2−95.6%0.1% | 3.8−18.2%2.5% | 4.0−17.9%2.3% | 4.2—4.5% | 4.4—11.5% | 4.6—9.4% | 4.9—8.3% | |
| Total liabilities | 121—36.5% | 121+183%36.5% | 123+329%33.2% | 48+82.2%14.6% | 50+100%14.1% | 43+72.4%33.7% | 29+6.8%21.4% | 26−15.8%17.0% | 25−30.8%14.7% | 25—26.6% | 27—70.0% | 31—62.7% | 36—61.5% | |
| Retained earnings | −422—−128% | −422—−128% | −380—−103% | −339—−104% | −305—−85.7% | −275—−217% | −250—−187% | −224—−146% | −200—−117% | −193—−207% | −180—−471% | −169—−342% | −159—−271% | |
| Shareholders' equity | 210—63.5% | 210+150%63.5% | 246+135%66.8% | 279+118%85.4% | 306+110%85.9% | 84+22.9%66.3% | 105+813%78.6% | 128+592%83.0% | 145+544%85.3% | 68—73.4% | 12—30.0% | 18—37.3% | 23—38.5% | |
| Total liabilities and equity | 330—100% | 330+161%100% | 369+176%100% | 326+112%100% | 356+109%100% | 126+36.0%100% | 134+249%100% | 154+211%100% | 170+190%100% | 93—100% | 38—100% | 49—100% | 59—100% | |
| Shares outstanding | 58—— | 58+27.2%— | 58+27.1%— | 58+26.2%— | 57+25.9%— | 46+13.4%— | 46+42.9%— | 46+44.5%— | 46+46.3%— | 40—— | 32—— | 32—— | 31—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.5+41.9%— | 0.9*+82.1%— | 0.6*+15.5%— | 0.5+31.9%— | 0.5*+33.8%— | 0.5*+37.0%— | 0.5*+36.2%— | 0.4+22.3%— | 0.4*+22.1%3.4% | 0.4*—16.0% | 0.4*—9.0% | 0.3—6.8% | 0.3*—2.5% | |
| Share-based compensation | — | — | — | — | 3.8*+67.3%— | 4.0+94.9%— | 3.6+69.4%— | 5.7+75.8%— | 2.3*+23.3%20.6% | 2.1—90.7% | 2.2—54.2% | 3.3—66.5% | 1.9*—15.4% | |
| Cash from operating activities | −120—— | −36*—— | −31*—— | −29—— | −24*—— | −20*—— | −20*—— | −6.4—— | −15*—−133% | −12*—−515% | −12*—−309% | −1.3—−25.9% | −12*—−95.9% | |
| Capital expenditure | −13—— | −1.8*—— | −4.1*—— | −5.1—— | −1.7*—— | −0.1*—— | −0.3*—— | −0.9—— | −0.5*—−4.4% | −0.0*—−0.4% | −0.1*—−1.5% | −0.6—−12.4% | −0.6*—−4.6% | |
| Cash from investing activities | −100—— | 60*+276%— | −49*−435%— | −155−747%— | 43*—— | 16*+696%— | 15*−1.0%— | 24—— | −123*—−1108% | 2.0*—88.6% | 15*—370% | −9.5—−194% | −5.9*—−48.5% | |
| Shares issued | — | — | — | — | — | — | — | — | 81*+249%726% | 67*—2972% | 2.0*—50.0% | 2.3—46.7% | 23*—192% | |
| Cash from financing activities | 246+203%— | 0.1*+1176%— | −4.2*−21770%— | 1.5+2821%— | 249*+207%— | 0.0*−100.0%— | 0.0*−99.1%— | 0.1−97.8%— | 81*+250%729% | 67*—2977% | 2.1*—52.0% | 2.3—46.7% | 23*—192% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Capricor Therapeutics, Inc. sells: revenue by product line, fiscal 2024#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Single reportable segment$22 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2024
Executive pay at Capricor Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Linda Marbán | $3.5 M | $7.2 M | $1.5 M | $748 |
| 2024Linda Marban | $1.5 M | $5.1 M | $900 K | $358 |
| 2023Linda Marban | $774 K | $1.2 M | $741 K | $127 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Capricor Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 2 · New debt 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2017 | $4 M | Private placement after listing | $2 to $10 million | 4 | equity | SEC |
| Feb 2015 | $7 M | Private placement after listing | $2 to $10 million | 8 | equity | SEC |
| Jan 2015 | $10 M | Private placement after listing | $10 to $50 million | 39 | equity | SEC |
| Nov 2013 | $26 M | Private placement after listing | $10 to $50 million | 34 | equity | SEC |
| Jun 2011 | $3 M | No. 2 | $2 to $10 million | 6 | equity, options | SEC |
| Jul 2009 | $2 M | No. 1 | $2 to $10 million | 24 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Capricor Therapeutics, Inc.#
$110 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2026
CHECKMATE GOVERNMENT RELATIONS $110 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $110 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Capricor Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Capricor Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2021 for 2 positions, at a median wage of $97 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Clinical Trial ManagerNatural Sciences Managers | 1 | $128 K |
| Research AssociateMolecular and Cellular Biologists | 1 | $67 K |
Where: West Hollywood, CA 1 · Beverly Hills, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2021 | 2 | 2 | $97 K | 2 |
| FY2020 | 1 | 1 | $75 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Capricor Therapeutics, Inc.
How Capricor Therapeutics, Inc. compares in Biotechnology
- Market cap$356 M · higher than 54% of 726
- Revenue$0 M · higher than 0% of 647
- Revenue growth-11.6% · higher than 33% of 438
- Price / book1.2× · lower than 76% of 534
- FCF yield-20.4% · higher than 44% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Capricor Therapeutics, Inc.🇺🇸 | $356 M | — | — | -11.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 23, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing, SEC annual report, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Capricor Therapeutics, Inc.? Verify and update this profile — free
Show Capricor Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.